[1] ZHANG Z H, YANG L, HOU J, et al. Promising positive liver targeting delivery system based on arabinogalactan-anchored polymeric micelles of norcantharidin[J]. Artif Cells Nanomed Biotechnol,2018,46(sup3):S630-S640. doi:  10.1080/21691401.2018.1505742
[2] ChANG C, ZHU Y Q, TANG X T, et al. The anti-proliferative effects of norcantharidin on human HepG2 cells in cell culture[J]. Mol Biol Rep,2011,38(1):163-169. doi:  10.1007/s11033-010-0090-6
[3] LAWRENCE M, REES G D. Microemulsion-based media as novel drug delivery systems[J]. Adv Drug Deliv Rev,2000,45(1):89-121. doi:  10.1016/S0169-409X(00)00103-4
[4] 李柏, 朱立峰, 张亚妮, 等. 去甲斑蝥素两种注射剂型小鼠急性毒性比较[J]. 中西医结合学报, 2007, 5(1):74-77.
[5] WANG S B, GUO S R, CHENG L. Disodium norcantharidate loaded poly(Epsilon-caprolactone) microspheres I. Preparation and evaluation[J]. Int J Pharm,2008,350(1-2):130-137. doi:  10.1016/j.ijpharm.2007.08.030
[6] 李琦, 范忠泽, 李先茜, 等. 去甲斑蝥素微球介入治疗大鼠肝癌疗效及其机制研究[J]. 中西医结合学报, 2006, 4(4):378-383.
[7] 吴卫平, 王宁. 微球用于肝肿瘤介入治疗中的效果观察[J]. 中华肿瘤防治杂志, 2016, 23(S2):22-23.
[8] 文庆怡, 张光宇, 周晓峰, 等. 去甲斑蝥素-N-乳糖酰壳聚糖/丝素蛋白微球在兔体内的抗肿瘤作用[J]. 中国新药杂志, 2014, 23(9):1075-1080.
[9] LIN X, ZHANG B, ZHANG K R, et al. Preclinical evaluations of norcantharidin-loaded intravenous lipid microspheres with low toxicity[J]. Expert Opin Drug Deliv,2012,9(12):1449-1462. doi:  10.1517/17425247.2012.724675
[10] 李素珍, 刘为萍, 朱静, 等. 去甲斑蝥素立方液晶纳米粒制备及体外释放度研究[J]. 中华中医药杂志, 2017, 32(12):5566-5568.
[11] CAPAN Y, WOO B H, GEBREKIDAN S, et al. Preparation and characterization of poly (D, L-lactide-co-glycolide) microspheres for controlled release of poly(L-lysine) complexed plasmid DNA[J]. Pharm Res,1999,16(4):509-513. doi:  10.1023/A:1018862827426
[12] 郑连英. 甲壳低聚糖的研究进展[J]. 材料科学与工程, 1999, 17(3):97-100.
[13] ELGADIR M A, UDDIN M S, FERDOSHH S, et al. Impact of chitosan composites and chitosan nanoparticle composites on various drug delivery systems: a review[J]. J Food Drug Anal,2015,23(4):619-629. doi:  10.1016/j.jfda.2014.10.008
[14] 徐晓莉, 李晓森, 王钦, 等. 人肝肿瘤细胞SMMC-7721、HepG2对去甲斑蝥素-半乳糖修饰壳聚糖纳米粒的摄入及S180荷瘤小鼠在体抗肿瘤活性的影响[J]. 中国老年学杂志, 2017, 37(15):3661-3664. doi:  10.3969/j.issn.1005-9202.2017.15.009
[15] DING X Y, HONG C J, LIU Y, et al. Pharmacokinetics, tissue distribution, and metabolites of a polyvinylpyrrolidone-coated norcantharidin chitosan nanoparticle formulation in rats and mice, using LC-MS/MS[J]. Int J Nanomedicine,2012,7:1723-1735.
[16] 张亚会. 甘草次酸囊泡包裹的N-乳糖酰壳聚糖纳米粒的制备及质量评价[D]. 兰州: 甘肃中医药大学, 2016.
[17] 李文渊, 童丽, 热增才旦. 纳米胶束作为药物载体的研究进展[J]. 中国执业药师, 2009, 6(12):36-40.
[18] 王琳, 陆丹玉, 方晨. 去甲斑蝥素纳米胶束的制备及抑瘤作用研究[J]. 中国药房, 2017, 28(19):2680-2684. doi:  10.6039/j.issn.1001-0408.2017.19.25
[19] 王琳, 张雅娟, 杨智钧, 等. 碳酸酐酶Ⅸ抗体修饰去甲斑蝥素纳米胶束的肺靶向性研究[J]. 中药药理与临床, 2017, 33(1):52-56.
[20] HE C, HU Y P, YIN L C, et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles[J]. Biomaterials,2010,31(13):3657-3666. doi:  10.1016/j.biomaterials.2010.01.065
[21] 顾宗林, 王佳明, 郭哲宁, 等. 去甲斑蝥素脂质体的制备及其体外释放特性的研究[J]. 抗感染药学, 2012, 9(4):277-280. doi:  10.3969/j.issn.1672-7878.2012.04-009
[22] 周奕, 叶建林. 乳糖化-去甲斑蝥素磷脂复合物pH敏感型脂质体肝靶向抗肿瘤活性研究[J]. 中草药, 2014, 45(19):2803-2808.
[23] 周奕, 许静玉, 管敏, 等. 乳糖化-去甲斑蝥素磷脂复合物及其pH敏感型脂质体的制备[J]. 中国新药杂志, 2011, 20(17):1631-1638.
[24] 熊友香, 汤红霞, 马瑞, 等. 去甲斑蝥素/粉防己碱双载药脂质体的制备工艺及体外释放性质考察[J]. 中国中药杂志, 2018, 43(12):2531-2536.
[25] 张莉. 肝靶向去甲斑蝥素微乳的研究[D]. 成都: 四川大学, 2004.